Biological Products, (No Diagnostic Substances) Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Biological Products, (No Diagnostic Substances)
100 results - 
- 
- 
- 
- 
- 
- - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2020-11-27 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $2.40 | +4,200 | 207,400 | +2% | +$10,068 | |||||
2020-11-27 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | S - Sale | $2.31 | -3,200 | 207,400 | -2% | -$7,380 | ||||||
2020-11-30 | BDTX | Black Diamond Therapeutics, Inc. | Bolzon Bradley J Phd | Dir, 10% | S - Sale | $33.15 | -10,393 | 1,680,323 | -1% | -$344,513 | ||||||
2020-11-30 | BDTX | Black Diamond Therapeutics, Inc. | Versant Venture Capital Vi, L.P. | 10% | S - Sale | $33.15 | -10,393 | 5,606,424 | 0% | -$344,513 | ||||||
| D | 2020-11-27 | VIR | Vir Biotechnology, Inc. | Virgin Herbert | EVP, Research, CSO | S - Sale+OE | $30.00 | -2,930 | 23,700 | -11% | -$87,900 | |||||
| D | 2020-11-30 | MRNA | Moderna, Inc. | Zaks Tal Zvi | Chief Medical Officer | S - Sale+OE | $147.76 | -20,000 | 0 | -100% | -$2,955,187 | |||||
2020-11-30 | BIIB | Biogen Inc. | Vounatsos Michel | CEO | P - Purchase | $241.31 | +3,100 | 34,810 | +10% | +$748,047 | ||||||
2020-11-27 | MRNA | Moderna, Inc. | Bancel Stephane | CEO | S - Sale | $119.22 | -21,046 | 15,913,942 | 0% | -$2,509,220 | ||||||
2020-11-30 | PSTI | Pluristem Therapeutics Inc | Clover Wolf Capital - Limited Partnership | 10% | P - Purchase | $9.70 | +20,000 | 4,077,589 | 0% | +$194,000 | ||||||
| ADM | 2019-01-02 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Officer | S - Sale+OE | $19.44 | -17,500 | 250,000 | -7% | -$340,168 | |||||
| AD | 2018-12-03 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Officer | S - Sale+OE | $18.45 | -17,500 | 250,000 | -7% | -$322,834 | |||||
| AD | 2018-11-15 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Officer | S - Sale+OE | $18.07 | -17,500 | 250,000 | -7% | -$316,157 | |||||
| D | 2020-11-27 | STRO | Sutro Biopharma, Inc. | Hallam Trevor | Chief Scientific Officer | S - Sale+OE | $17.01 | -2,393 | 36,712 | -6% | -$40,713 | |||||
| M | 2020-11-25 | HALO | Halozyme Therapeutics, Inc. | Kelley Kenneth J | Dir | S - Sale | $41.37 | -19,671 | 266,711 | -7% | -$813,850 | |||||
2020-11-25 | MRNA | Moderna, Inc. | Bancel Stephane | CEO | S - Sale | $99.20 | -9,000 | 23,589,868 | 0% | -$892,800 | ||||||
| D | 2020-11-24 | EXEL | Exelixis, Inc. | Marchesi Vincent T | Dir | S - Sale+OE | $18.50 | -40,004 | 90,212 | -31% | -$740,074 | |||||
2020-11-25 | HALO | Halozyme Therapeutics, Inc. | Henderson Jeffrey William | Dir | S - Sale | $40.08 | -24,498 | 47,609 | -34% | -$981,757 | ||||||
2020-11-25 | HALO | Halozyme Therapeutics, Inc. | Daly James M | Dir | S - Sale | $40.41 | -10,363 | 21,002 | -33% | -$418,800 | ||||||
| D | 2020-11-25 | HALO | Halozyme Therapeutics, Inc. | Torley Helen | Pres, CEO | S - Sale+OE | $40.73 | -50,000 | 480,522 | -9% | -$2,036,568 | |||||
| D | 2020-11-24 | VIR | Vir Biotechnology, Inc. | Virgin Herbert | EVP, Research, CSO | S - Sale+OE | $27.29 | -2,340 | 23,700 | -9% | -$63,848 | |||||
| DM | 2020-11-23 | MRNA | Moderna, Inc. | Hoge Stephen | Pres | S - Sale+OE | $99.89 | -20,000 | 1,890,646 | -1% | -$1,997,711 | |||||
| D | 2020-11-23 | CRDF | Cardiff Oncology, Inc. | Kelemen Vicki | EVP, COO | S - Sale+OE | $18.60 | -35,321 | 5,054 | -87% | -$657,020 | |||||
| D | 2020-11-23 | ADPT | Adaptive Biotechnologies Corp | Taylor Stacy L | SVP, GC | S - Sale+OE | $46.30 | -2,880 | 1,300 | -69% | -$133,359 | |||||
2020-11-23 | PDLI | Pdl Biopharma, Inc. | O'Farrell Elizabeth G. | Dir | S - Sale | $2.44 | -25,826 | 0 | -100% | -$63,015 | ||||||
2020-11-23 | PDLI | Pdl Biopharma, Inc. | Gryska David W | Dir | S - Sale | $2.43 | -50,000 | 105,337 | -32% | -$121,500 | ||||||
| D | 2020-11-20 | KOD | Kodiak Sciences Inc. | Ehrlich Jason | See Remarks | S - Sale+OE | $138.79 | -6,950 | 42,843 | -14% | -$964,601 | |||||
| M | 2020-11-20 | CASI | Casi Pharmaceuticals, Inc. | He Wei-Wu | COB, CEO | P - Purchase | $2.15 | +227,471 | 13,037,413 | +2% | +$488,239 | |||||
| D | 2020-11-23 | MRNA | Moderna, Inc. | Zaks Tal Zvi | Chief Medical Officer | S - Sale+OE | $100.53 | -15,000 | 0 | -100% | -$1,507,963 | |||||
2020-11-20 | MRNA | Moderna, Inc. | Bancel Stephane | CEO | S - Sale | $95.10 | -17,514 | 14,537,006 | 0% | -$1,665,581 | ||||||
| D | 2020-11-23 | VCEL | Vericel Corp | Zerbe Robert L Md | Dir | S - Sale+OE | $23.55 | -17,500 | 31,795 | -36% | -$412,125 | |||||
2020-11-23 | MGTX | Meiragtx Holdings Plc | Perceptive Advisors LLC | Dir, 10% | P - Purchase | $12.85 | +500,000 | 6,933,277 | +8% | +$6,425,000 | ||||||
2020-11-23 | VXRT | Vaxart, Inc. | Latour Wouter | Dir | S - Sale | $6.32 | -333,334 | 0 | -100% | -$2,108,138 | ||||||
| D | 2020-11-19 | SGEN | Seagen Inc. | Gryska David W | Dir | S - Sale+OE | $173.70 | -15,000 | 44,848 | -25% | -$2,605,523 | |||||
| D | 2020-11-19 | RGEN | Repligen Corp | Hunt Anthony | CEO | S - Sale+OE | $185.80 | -20,000 | 233,327 | -8% | -$3,716,051 | |||||
2020-11-19 | JNCE | Jounce Therapeutics, Inc. | Third Rock Ventures Ii, L.P. | 10% | S - Sale | $7.00 | -15,000 | 9,361,137 | 0% | -$105,075 | ||||||
2020-11-19 | BDTX | Black Diamond Therapeutics, Inc. | Versant Venture Capital Vi, L.P. | 10% | S - Sale | $33.01 | -130,017 | 7,646,829 | -2% | -$4,291,861 | ||||||
2020-11-19 | JNCE | Jounce Therapeutics, Inc. | Pfeffer Cary | Dir | S - Sale | $0.00 | -0 | 9,917 | 0% | -$0 | ||||||
2020-11-19 | BDTX | Black Diamond Therapeutics, Inc. | Bolzon Bradley J Phd | Dir, 10% | S - Sale | $33.01 | -130,017 | 6,693,509 | -2% | -$4,291,861 | ||||||
| D | 2020-11-19 | ADPT | Adaptive Biotechnologies Corp | Benzeno Sharon | Chief Business Development Off | S - Sale+OE | $48.86 | -416 | 0 | -100% | -$20,326 | |||||
2020-11-18 | PDLI | Pdl Biopharma, Inc. | O'Farrell Elizabeth G. | Dir | S - Sale | $2.38 | -63,291 | 25,826 | -71% | -$150,696 | ||||||
| D | 2020-11-20 | PDLI | Pdl Biopharma, Inc. | Bazaar Alan Lee | Dir | S - Sale+OE | $2.42 | -33,435 | 10,438 | -76% | -$81,003 | |||||
2020-11-20 | HALO | Halozyme Therapeutics, Inc. | Labarre Michael J. | SVP, Chief Technical Officer | S - Sale | $38.76 | -12,000 | 134,800 | -8% | -$465,176 | ||||||
| DM | 2020-11-18 | NSTG | Nanostring Technologies Inc | Bailey K Thomas | CFO | S - Sale+OE | $47.62 | -18,646 | 0 | -100% | -$887,926 | |||||
| D | 2020-11-18 | TECH | Bio-Techne Corp | Baumgartner Robert V | Dir | S - Sale+OE | $303.33 | -5,000 | 9,612 | -34% | -$1,516,675 | |||||
| M | 2020-11-18 | MRNA | Moderna, Inc. | Bancel Stephane | CEO | S - Sale | $91.73 | -19,000 | 23,617,382 | 0% | -$1,742,830 | |||||
| M | 2020-11-17 | BDTX | Black Diamond Therapeutics, Inc. | Bolzon Bradley J Phd | Dir, 10% | S - Sale | $33.05 | -4,730 | 6,808,363 | 0% | -$156,349 | |||||
| M | 2020-11-17 | BDTX | Black Diamond Therapeutics, Inc. | Versant Venture Capital Vi, L.P. | 10% | S - Sale | $33.05 | -4,730 | 7,776,846 | 0% | -$156,349 | |||||
| DM | 2020-11-17 | ADPT | Adaptive Biotechnologies Corp | Robins Chad M | CEO, COB | S - Sale+OE | $46.99 | -50,040 | 1,778,180 | -3% | -$2,351,429 | |||||
| M | 2020-11-17 | MGTX | Meiragtx Holdings Plc | Forbes Alexandria | Pres, CEO | S - Sale | $15.16 | -16,610 | 1,369,171 | -1% | -$251,781 | |||||
| AM | 2020-11-10 | MGTX | Meiragtx Holdings Plc | Forbes Alexandria | Pres, CEO | S - Sale | $15.03 | -26,019 | 1,385,781 | -2% | -$391,149 | |||||
2020-11-17 | JNCE | Jounce Therapeutics, Inc. | Pfeffer Cary | Dir | S - Sale | $0.00 | -0 | 9,917 | 0% | -$0 | ||||||
2020-11-17 | JNCE | Jounce Therapeutics, Inc. | Third Rock Ventures Ii, L.P. | 10% | S - Sale | $7.25 | -15,000 | 9,376,137 | 0% | -$108,773 | ||||||
| M | 2020-11-17 | PDLI | Pdl Biopharma, Inc. | Gryska David W | Dir | S - Sale | $2.40 | -150,000 | 95,337 | -61% | -$359,500 | |||||
| D | 2020-11-17 | TCRR | Tcr2 Therapeutics Inc. | Somaiya Mayur Ian | CFO | S - Sale+OE | $30.00 | -3,666 | 1,473 | -71% | -$109,980 | |||||
2020-11-17 | ORGO | Organogenesis Holdings Inc. | Ades Alan A. | Dir, 10% | P - Purchase | $3.25 | +833,153 | 137,242,799 | +1% | +$2,707,747 | ||||||
| DM | 2020-11-17 | CHRS | Coherus Biosciences, Inc. | Anicetti Vincent R | COO | S - Sale+OE | $17.72 | -22,770 | 32,569 | -41% | -$403,510 | |||||
| D | 2020-11-17 | CHRS | Coherus Biosciences, Inc. | Viret Jean-Frederic | CFO | S - Sale+OE | $17.49 | -1,995 | 40,269 | -5% | -$34,896 | |||||
| D | 2020-11-09 | TECH | Bio-Techne Corp | Seth Alpna | Dir | S - Sale+OE | $306.62 | -5,023 | 2,139 | -70% | -$1,540,167 | |||||
| D | 2020-11-16 | ADPT | Adaptive Biotechnologies Corp | Lo Francis | Chief People Officer | S - Sale+OE | $47.68 | -2,000 | 2,500 | -44% | -$95,351 | |||||
| D | 2020-11-16 | ADPT | Adaptive Biotechnologies Corp | Griffin Michelle Renee | Dir | S - Sale+OE | $47.69 | -6,000 | 0 | -100% | -$286,135 | |||||
| D | 2020-11-16 | ADPT | Adaptive Biotechnologies Corp | Hershberg Robert | Dir | S - Sale+OE | $47.69 | -2,000 | 0 | -100% | -$95,381 | |||||
2020-11-16 | REPL | Replimune Group, Inc. | Love Colin | COO | S - Sale | $44.91 | -15,000 | 1,006,524 | -1% | -$673,649 | ||||||
2020-11-16 | RVMD | Revolution Medicines, Inc. | Column Group Iii, LP | 10% | S - Sale | $36.40 | -2,027,156 | 5,950,228 | -25% | -$73,788,478 | ||||||
2020-11-16 | RVMD | Revolution Medicines, Inc. | Svennilson Peter | Dir, 10% | S - Sale | $36.40 | -2,027,156 | 3,806,436 | -35% | -$73,788,478 | ||||||
| M | 2020-11-16 | ENZN | Enzon Pharmaceuticals, Inc. | Read Randolph C | Dir | P - Purchase | $0.15 | +100,450 | 100,450 | New | +$15,498 | |||||
| D | 2020-11-16 | NVAX | Novavax Inc | Erck Stanley C | Pres, CEO | S - Sale+OE | $90.65 | -52,316 | 20,495 | -72% | -$4,742,667 | |||||
2020-11-16 | ALLO | Allogene Therapeutics, Inc. | Schmidt Eric Thomas | CFO | S - Sale | $32.88 | -15,000 | 1,261,511 | -1% | -$493,146 | ||||||
| D | 2020-11-16 | NSTG | Nanostring Technologies Inc | Brown J. Chad | SVP, Sales, Marketing | S - Sale+OE | $46.21 | -6,281 | 440 | -93% | -$290,245 | |||||
| D | 2020-11-16 | NSTG | Nanostring Technologies Inc | Hershberg Robert | Dir | S - Sale+OE | $46.67 | -1,500 | 1,890 | -44% | -$70,002 | |||||
2020-11-17 | ATRA | Atara Biotherapeutics, Inc. | Koppikar Utpal | CFO | S - Sale | $19.77 | -1,469 | 132,061 | -1% | -$29,048 | ||||||
2020-11-17 | ATRA | Atara Biotherapeutics, Inc. | Newell Joe | Chief Operations Officer | S - Sale | $19.77 | -1,648 | 116,555 | -1% | -$32,588 | ||||||
2020-11-17 | ATRA | Atara Biotherapeutics, Inc. | Touchon Pascal | Pres, CEO | S - Sale | $19.77 | -4,716 | 255,321 | -2% | -$93,254 | ||||||
2020-11-17 | CVM | Cel Sci Corp | Young Peter R | Dir | P - Purchase | $11.68 | +800 | 25,814 | +3% | +$9,343 | ||||||
2020-11-18 | CVM | Cel Sci Corp | Baillavoine Bruno Jean-Marie | Dir | P - Purchase | $11.77 | +800 | 4,723 | +20% | +$9,416 | ||||||
2020-11-18 | CVM | Cel Sci Corp | Watson Robert Eugene | Dir | P - Purchase | $11.77 | +800 | 3,181 | +34% | +$9,416 | ||||||
| M | 2020-11-13 | BDTX | Black Diamond Therapeutics, Inc. | Versant Venture Capital Vi, L.P. | 10% | S - Sale | $33.74 | -4,700 | 7,781,576 | 0% | -$158,587 | |||||
| M | 2020-11-13 | BDTX | Black Diamond Therapeutics, Inc. | Bolzon Bradley J Phd | Dir, 10% | S - Sale | $33.74 | -4,700 | 6,812,541 | 0% | -$158,587 | |||||
2020-11-13 | ENZN | Enzon Pharmaceuticals, Inc. | Bleznick Jordan | Dir | P - Purchase | $0.15 | +100,000 | 100,000 | New | +$15,380 | ||||||
| D | 2020-11-16 | MRNA | Moderna, Inc. | Zaks Tal Zvi | Chief Medical Officer | S - Sale+OE | $96.99 | -15,000 | 0 | -100% | -$1,454,830 | |||||
2020-11-12 | NBIX | Neurocrine Biosciences Inc | Benevich Eric | Chief Commercial Officer | S - Sale | $90.71 | -2,257 | 17,405 | -11% | -$204,723 | ||||||
2020-11-12 | NBIX | Neurocrine Biosciences Inc | Roberts Eiry | Chief Medical Officer | S - Sale | $90.74 | -2,257 | 13,477 | -14% | -$204,810 | ||||||
2020-11-12 | NBIX | Neurocrine Biosciences Inc | Lloyd-Smith Malcolm | Chief Regulatory Officer | S - Sale | $90.73 | -2,257 | 29,002 | -7% | -$204,776 | ||||||
2020-11-12 | NBIX | Neurocrine Biosciences Inc | Lippoldt Darin | GC | S - Sale | $90.72 | -2,257 | 30,082 | -7% | -$204,755 | ||||||
2020-11-12 | NBIX | Neurocrine Biosciences Inc | Grigoriadis Dimitri E. | CHIEF RESEARCH OFFICER | S - Sale | $90.73 | -2,257 | 81,624 | -3% | -$204,784 | ||||||
2020-11-12 | NBIX | Neurocrine Biosciences Inc | Gorman Kevin Charles | CEO | S - Sale | $90.78 | -3,390 | 441,071 | -1% | -$307,748 | ||||||
2020-11-12 | NBIX | Neurocrine Biosciences Inc | Gano Kyle | Chief Business Development Off | S - Sale | $90.73 | -2,257 | 98,028 | -2% | -$204,770 | ||||||
2020-11-12 | NBIX | Neurocrine Biosciences Inc | Cooke Julie | CHRO | S - Sale | $90.73 | -2,257 | 11,580 | -16% | -$204,778 | ||||||
2020-11-12 | NBIX | Neurocrine Biosciences Inc | Bozigian Haig P. | CHIEF DEVELOPMENT OFFICER | S - Sale | $90.74 | -2,257 | 152,694 | -1% | -$204,806 | ||||||
2020-11-12 | NBIX | Neurocrine Biosciences Inc | Abernethy Matt | CFO | S - Sale | $90.74 | -2,257 | 10,014 | -18% | -$204,810 | ||||||
| DM | 2020-11-12 | TWST | Twist Bioscience Corp | Weiss Patrick | COO | S - Sale+OE | $105.05 | -7,100 | 55,578 | -11% | -$745,855 | |||||
2020-11-16 | FATE | Fate Therapeutics Inc | Shoemaker Daniel D | Chief Scientific Officer | S - Sale | $51.83 | -25,000 | 93,091 | -21% | -$1,295,746 | ||||||
2020-11-13 | CVM | Cel Sci Corp | Cipriano John | SVP | S - Sale | $12.73 | -10,000 | 73,108 | -12% | -$127,290 | ||||||
| D | 2020-11-13 | ATRA | Atara Biotherapeutics, Inc. | Newell Joe | Chief Operations Officer | S - Sale+OE | $18.49 | -7,500 | 118,203 | -6% | -$138,688 | |||||
| DM | 2020-11-12 | MRNA | Moderna, Inc. | Hoge Stephen | Pres | S - Sale+OE | $86.82 | -20,000 | 1,900,646 | -1% | -$1,736,475 | |||||
| M | 2020-11-12 | MRNA | Moderna, Inc. | Bancel Stephane | CEO | S - Sale | $86.05 | -21,046 | 15,962,502 | 0% | -$1,810,902 | |||||
| DM | 2020-11-12 | FATE | Fate Therapeutics Inc | Wolchko J Scott | Pres, CEO | S - Sale+OE | $51.87 | -60,000 | 419,969 | -13% | -$3,112,424 | |||||
2020-11-11 | ADPT | Adaptive Biotechnologies Corp | Viking Global Investors LP | 10% | S - Sale | $49.52 | -2,500,000 | 30,993,708 | -7% | -$123,787,500 | ||||||
2020-11-11 | ADPT | Adaptive Biotechnologies Corp | Viking Global Performance LLC | 10% | S - Sale | $49.52 | -2,500,000 | 30,993,708 | -7% | -$123,787,500 | ||||||
2020-11-11 | SURF | Surface Oncology, Inc. | Ross Robert W. | Chief Medical Officer | S - Sale | $10.05 | -595 | 100,405 | -1% | -$5,980 | ||||||
2020-11-12 | BDTX | Black Diamond Therapeutics, Inc. | Versant Venture Capital Vi, L.P. | 10% | S - Sale | $34.15 | -15,598 | 5,927,001 | 0% | -$532,642 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |